Johnson & Johnson discontinues the Phase 3 SunRISe-2 trial for TAR-200 in bladder cancer, citing lack of superiority. Q3 ...

Final results from the SWOG S1011 randomized Phase III clinical trial, published in the New England Journal of Medicine, ...

Patients with muscle-invasive bladder cancer experienced safe medical and surgical treatment with the NURE-combo.

Enfortumab vedotin plus pembrolizumab was previously granted a priority review designation from the MHLW.

The SWOG S1011 trial shows no survival benefit from extended lymphadenectomy in bladder cancer, revealing higher complications and mortality post-surgery.

The SWOG S1011 randomized phase 3 trial found no significant improvement in disease-free or overall survival but a higher ...

Eligible patients had urothelial cancer of clinical stage ... of T4b tumor status or metastasis (in 6), no muscle-invasive bladder cancer (in 8), a lack of pretrial scans (in 1), and randomization ...

TORONTO, ON / ACCESSWIRE / October 7, 2024 / Theralase® Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development ...

The SWOG S1011 randomized phase 3 trial found no significant improvement in disease-free or overall survival but a higher ...

Ferring Pharmaceuticals today announced the opening of a state-of-the-art global manufacturing hub in Finland for the drug ...

the Foundation of Urological Research (Ove and Carin Carlsson bladder cancer donation), and Hillevi Fries Research Foundation. The funding sources had no role in the study design, data analyses, ...